Literature DB >> 14568907

Fatal hepatic necrosis following imatinib mesylate therapy.

Nancy U Lin, Stefanie Sarantopoulos, James R Stone, Ilene Galinsky, Richard M Stone, Daniel J Deangelo, Robert J Soiffer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14568907     DOI： 10.1182/blood-2003-07-2323

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  14 in total

1.  Imatinib mesylate (gleevec) hepatotoxicity.

Authors:  Ayse L Mindikoglu; Arie Regev; Pablo A Bejarano; Enrique J Martinez; Lennox J Jeffers; Eugene R Schiff
Journal:  Dig Dis Sci       Date:  2007-01-12       Impact factor: 3.199

2.  Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management.

Authors:  Katsuya Ikuta; Yoshihiro Torimoto; Junko Jimbo; Junki Inamura; Motohiro Shindo; Kazuya Sato; Yoshihiko Tokusashi; Naoyuki Miyokawa; Yutaka Kohgo
Journal:  Int J Hematol       Date:  2005-11       Impact factor: 2.490

Review 3.  Kinase inhibitors and monoclonal antibodies in oncology: clinical implications.

Authors:  Helen Gharwan; Hunter Groninger
Journal:  Nat Rev Clin Oncol       Date:  2015-12-31       Impact factor: 66.675

Review 4.  Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.

Authors:  Rashmi R Shah; Joel Morganroth; Devron R Shah
Journal:  Drug Saf       Date:  2013-07       Impact factor: 5.606

5.  Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors.

Authors:  Onder Tonyali; Ugur Coskun; Ramazan Yildiz; Tarkan Karakan; Umut Demirci; Nalan Akyurek; Mustafa Benekli; Suleyman Buyukberber
Journal:  Med Oncol       Date:  2009-08-07       Impact factor: 3.064

Review 6.  Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity.

Authors:  Ayako Arai; Weihua Yan; Shihoko Wakabayashi; Shin Hayashi; Johji Inazawa; Osamu Miura
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

7.  Imatinib-induced fatal acute liver failure.

Authors:  Ezequiel Ridruejo; Roberto Cacchione; Alejandra G Villamil; Sebastián Marciano; Adrián C Gadano; Oscar G Mandó
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

8.  Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase.

Authors:  Tariq I Mughal; Andrew Schrieber
Journal:  Biologics       Date:  2010-12-02

9.  Tumor lysis syndrome soon after treatment with hydroxyurea followed by nilotinib in two patients with chronic-phase chronic myelogenous leukemia.

Authors:  Jian Hua; Yasunobu Iwaki; Morihiro Inoue; Masao Hagihara
Journal:  Int J Hematol       Date:  2013-05-07       Impact factor: 2.490

10.  Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

Authors:  Martin Henkes; Heiko van der Kuip; Walter E Aulitzky
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.